HomeCompareSNOTF vs PFE

SNOTF vs PFE: Dividend Comparison 2026

SNOTF yields 9.09% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNOTF wins by $232739.08M in total portfolio value
10 years
SNOTF
SNOTF
● Live price
9.09%
Share price
$0.45
Annual div
$0.04
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$232739.13M
Annual income
$227,921,478,612.36
Full SNOTF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SNOTF vs PFE

📍 SNOTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNOTFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNOTF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNOTF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNOTF
Annual income on $10K today (after 15% tax)
$772.52/yr
After 10yr DRIP, annual income (after tax)
$193,733,256,820.51/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SNOTF beats the other by $193,733,234,500.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNOTF + PFE for your $10,000?

SNOTF: 50%PFE: 50%
100% PFE50/50100% SNOTF
Portfolio after 10yr
$116369.59M
Annual income
$113,960,752,435.54/yr
Blended yield
97.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SNOTF
No analyst data
Altman Z
2.3
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNOTF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNOTFPFE
Forward yield9.09%6.13%
Annual dividend / share$0.04$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$232739.13M$49.6K
Annual income after 10y$227,921,478,612.36$26,258.71
Total dividends collected$232411.92M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SNOTF vs PFE ($10,000, DRIP)

YearSNOTF PortfolioSNOTF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,518$1,817.68$9,153$693.39+$3.4KSNOTF
2$17,647$4,252.93$8,593$849.25+$9.1KSNOTF
3$30,089$11,206.70$8,336$1,066.78+$21.8KSNOTF
4$67,911$35,715.92$8,437$1,384.80+$59.5KSNOTF
5$223,340$150,675.55$9,013$1,875.40+$214.3KSNOTF
6$1,165,198$926,224.28$10,306$2,680.72+$1.15MSNOTF
7$10,278,996$9,032,234.03$12,820$4,101.38+$10.27MSNOTF
8$159,931,972$148,933,445.63$17,673$6,826.70+$159.91MSNOTF
9$4,502,474,795$4,331,347,585.36$27,543$12,591.86+$4502.45MSNOTF
10$232,739,126,643$227,921,478,612.36$49,560$26,258.71+$232739.08MSNOTF

SNOTF vs PFE: Complete Analysis 2026

SNOTFStock

Sinotrans Limited provides integrated logistics services primarily in the People's Republic of China. The company operates through three segments: Forwarding and Related Business, Logistics, and E-commerce. It offers sea freight forwarding, such as space booking, arranging transportation, container delivery and loading, storage, port concentration and dispatch, customs declaration and inspection, distribution, and delivery; air freight forwarding, including pick-up and dispatch, warehousing, packaging, booking and handling, trunk air line freight forwarding, and trucking transit services; rail freight forwarding services; shipping agency services comprising port arrival and departure, documentation, ship supplies, and other ship related services at ports; and storage and terminal services, such as storage, container consolidating and devanning, cargo loading and unloading, dispatching and distribution, etc. The company also engages in the e-commerce business consisting of cross-border e-commerce logistics, logistics e-commerce platform, and logistics equipment sharing platform. In addition, it provides integrated logistics solutions, including contract, project, chemical, cold chain, and other logistics services; whole supply chain logistics services; and supply chain management services. Sinotrans Limited was founded in 1950 and is based in Beijing, the People's Republic of China.

Full SNOTF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SNOTF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNOTF vs SCHDSNOTF vs JEPISNOTF vs OSNOTF vs KOSNOTF vs MAINSNOTF vs JNJSNOTF vs MRKSNOTF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.